| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT02562417 Details | 2017-07-21 Interventional | 4 | 0 | Dexamethasone Neuromuscular B… | Change of practice in the department - | |||
| NCT02210104 Details | 2017-07-21 Interventional | 1 | 0 | Cyclophosphamid… Ipilimumab Melanoma Sarcoma | Issues with tetramer staining - | |||
| NCT01994967 Details | 2017-07-21 Interventional | 3 | 0 | Bupivacaine Levobupivacaine Musculoskeletal… Spinal Diseases Orthopedic Diso… | Another regulatory way was defined. - | |||
| NCT01067066 Details | 2017-07-21 Interventional | 1 | 21 | Temozolomide Melanoma | Phase I/II study halted as Phase I, Low Response Rate - | |||
| NCT01038739 2009-015158-39 Details | 2017-07-21 Interventional | 3 | [3 Refs] | 330 | Mesalamine Diverticulitis Recurrence | Stopped due to futility. - | ||
| NCT00384865 Details | 2017-07-21 Interventional | 2 | [1 Refs] | 64 | Aspirin Simvastatin Hypertension Hypertension, P… Pulmonary Arter… | - The primary end point that should be used in early-stage clinical trials in PAH is uncertain. We did not include invasive hemodynamic end points. Early termination led to missing data for those active subjects in the trial at termination (n16). | ||
| NCT02227368 Details | 2017-07-19 Interventional | 2 | 40 | Ticagrelor Peripheral Arte… Peripheral Arte… | - This study was terminated early for low enrolment. Less than 25% of anticipated number of subjects were enroled and there was an imbanlance between groups. Therefore, the results should be interpreted with caution. | |||
| NCT01550302 Details | 2017-07-18 Interventional | 4 | 10 | Bupivacaine Shoulder Pain | Unable to continue enrollment due to lack of resources (research coordinator no longer
available). - | |||
| NCT01459796 Details | 2017-07-18 Interventional | 3 | 220 | Allopurinol Rilonacept Gout | - - | |||
| NCT01526876 Details | 2017-07-17 Interventional | 4 | 0 | Clevidipine Hypertension | Terminated by Sponsor - | |||
| NCT00041470 Details | 2017-07-17 Interventional | 1/2 | 38 | Paclitaxel Trastuzumab Vinorelbine Breast Neoplasm… Breast Cancer | Sponsor withdrew the study - | |||
| NCT03193359 Details | 2017-07-14 Interventional | 3 | 0 | Botulinum Toxin… Botulinum Toxin… abobotulinumtox… Headache Migraine Disord… | Corporate Decision - | |||
| NCT03193346 Details | 2017-07-14 Interventional | 3 | 0 | Botulinum Toxin… Botulinum Toxin… abobotulinumtox… Headache Migraine Disord… | Corporation Decision - | |||
| NCT00811174 Details | 2017-07-14 Interventional | 3 | 5 | Immunoglobulins… Rho(D) Immune G… gamma-Globulins Immunologic Def… Primary Immunod… | Due to limited data available, efficacy, and PK analyses were not performed. - | |||
| NCT02633384 Details | 2017-07-13 Interventional | 4 | [8 Refs] | 52 | SMOFlipid Sorbitol Cholestasis Intrahepatic, C… | One of the intravenous lipid emulsions was retired from the market - | ||
| NCT02623478 2015-003353-18 Details | 2017-07-13 Interventional | 1 | 0 | Insulin Lispro Diabetes Mellit… Diabetes Mellit… | Change in clinical strategy - | |||
| NCT02623465 2015-003353-18 Details | 2017-07-13 Interventional | 1 | 0 | Insulin Lispro Diabetes Mellit… Diabetes Mellit… | Change in clinical strategy - | |||
| NCT02623452 2015-003351-21 Details | 2017-07-13 Interventional | 1 | 0 | Insulin Lispro Diabetes Mellit… Diabetes Mellit… | Change in clinical strategy - | |||
| NCT01309126 Details | 2017-07-13 Interventional | 3 | 217 | Cetuximab Colorectal Neop… Colorectal Canc… | Due to enrollment challenges resulting from changing treatment patterns in the use of
cetuximab, the study has been terminated. No patients remain on study. - | |||
| NCT03192969 2016-002697-12 Details | 2017-07-12 Interventional | 3 | 0 | Abatacept Glucocorticoids Arteritis Giant Cell Arte… Polymyalgia Rhe… | Business objectives have changed - |